DISPOSITION OF H-3 AFLATOXIN-B1 IN MICE - FORMATION AND RETENTION OF TISSUE BOUND METABOLITES IN NASAL GLANDS

被引:11
作者
LARSSON, P
HOEDAYA, WI
TJALVE, H
机构
[1] Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Swedish University of Agricultural Sciences, Uppsala Biomedical Centre, Uppsala, S-75123
来源
PHARMACOLOGY & TOXICOLOGY | 1990年 / 67卷 / 02期
关键词
D O I
10.1111/j.1600-0773.1990.tb00805.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Whole‐body autoradiography with 3H‐labelled aflatoxin B1 (3H‐AFB1) in C57B1‐mice showed a pronounced accumulation and retention of radioactivity in some nasal glands. At long survival intervals the labelling of the nasal glands was much higher than that of the liver. Experiments in vitro showed a capacity of the nasal glands to form tissue‐bound 3H‐AFB1‐metabolites. Incubations in the presence of glutathione decreased the levels of tissue‐bound 3H‐AFB1‐metabolites both in the liver and in the nasal glands, but the decrease was more pronounced in the former than in the latter tissue. The 3H‐AFB1‐metabolite‐binding to the nasal glands in vitro was inhibited by the cytochrome P‐450‐inhibitor metyrapone and by CO‐ and N2‐atmospheres indicating a cytochrome P‐450‐dependent bioactivation of the AFB1 in these glands. Cytochrome P‐450 was shown to be present in the glands although at a much lower level than in the liver. The glands in the nose, which were shown to have this AFB1‐metabolizing capacity, were the lateral nasal gland (Steno's gland) situated ventrally and laterally to the maxillary sinus and the large group of glands in the lateral nasal wall ventrally to the ostium of the maxillary sinus. Our results also indicated an AFB1 ‐metabolizing capacity of the serous glands which are present in the anterior part of the nasal septum. 1990 Nordic Pharmacological Society
引用
收藏
页码:162 / 171
页数:10
相关论文
共 22 条
[1]  
ARORA RG, 1984, ACTA PHARMACOL TOX, V43, P273
[2]   METABOLISM-DEPENDENT BINDING OF THE CHLORINATED INSECTICIDE DDT AND ITS METABOLITE, DDD, TO MICROSOMAL PROTEIN AND LIPIDS [J].
BAKER, MT ;
VANDYKE, RA .
BIOCHEMICAL PHARMACOLOGY, 1984, 33 (02) :255-260
[3]  
Busby WF, 1984, ACS MONOGR SER, V182, P945
[4]  
BUTLER WH, 1969, CANCER RES, V29, P2206
[5]   DIFFERENCES IN AFLATOXIN-B1-SUSCEPTIBILITY OF RAT AND MOUSE ARE CORRELATED WITH THE CAPABILITY INVITRO TO INACTIVATE AFLATOXIN-B1-EPOXIDE [J].
DEGEN, GH ;
NEUMANN, HG .
CARCINOGENESIS, 1981, 2 (04) :299-306
[6]   EFFECTS OF AFLATOXIN-B1 ON PREGNANT INBRED SPRAGUE-DAWLEY RATS AND THEIR F1 GENERATION - A CONTRIBUTION TO TRANS-PLACENTAL CARCINOGENESIS [J].
GOERTTLER, K ;
LOHRKE, H ;
SCHWEIZER, HJ ;
HESSE, B .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1980, 64 (06) :1349-1354
[7]   AFLATOXIN CARCINOGENESIS - INHIBITION OF LIVER CANCER INDUCTION IN HYPOPHYSECTOMIZED RATS [J].
GOODALL, CM ;
BUTLER, WH .
INTERNATIONAL JOURNAL OF CANCER, 1969, 4 (04) :422-&
[8]  
GURTOO HL, 1974, RES COMMUN CHEM PATH, V9, P107
[9]  
HERROLD MDK, 1969, BRIT J CANCER, V23, P655
[10]   METABOLISM OF AFLATOXIN-B1 IN THE BOVINE OLFACTORY MUCOSA [J].
LARSSON, P ;
PETTERSSON, H ;
TJALVE, H .
CARCINOGENESIS, 1989, 10 (06) :1113-1118